Krystal Biotech
KRYS
284 hedge funds and large institutions have $4.94B invested in Krystal Biotech in 2025 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 106 increasing their positions, 86 reducing their positions, and 32 closing their positions.
44% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 32
30% more capital invested
Capital invested by funds: $3.8B → $4.94B (+$1.14B)
23% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 86
3% more funds holding
Funds holding: 275 → 284 (+9)
1.08% more ownership
Funds ownership: 95.68% → 96.77% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
63% less call options, than puts
Call options by funds: $43.1M | Put options by funds: $116M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$90.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$30.8M |
| 3 |
Millennium Management
New York
|
+$20.4M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$17.6M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$31M |
| 2 |
Goldman Sachs
New York
|
-$27.3M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$19.9M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$13.7M |
| 5 |
Renaissance Technologies
New York
|
-$12.3M |
KRYS Hedge Fund Activity: Q3 2025 in Review
284 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2025, worth a combined $4.94B — up 30% from $3.8B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new KRYS positions and 32 closed out — a net gain of 14 holders — while 106 added to existing stakes and 86 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $90.2M. The largest seller was Braidwell, cutting an estimated $31M.
- 284 institutional investors held Krystal Biotech (KRYS) as of Q3 2025, up from 275 in Q2 2025.
- Funds reported $4.94B of Krystal Biotech stock for Q3 2025, up 30% quarter-over-quarter.
- 46 funds opened new Krystal Biotech positions in Q3 2025 and 32 closed out, a net change of +14 holders.
- The largest Krystal Biotech buyer in Q3 2025 was Citadel Advisors, an estimated $90.2M added.
- The largest Krystal Biotech seller in Q3 2025 was Braidwell, an estimated $31M sold.
Based on aggregated 13F filings for Q3 2025.